MCID: MCP008
MIFTS: 24

Mucoepidermoid Esophageal Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Mucoepidermoid Esophageal Carcinoma

MalaCards integrated aliases for Mucoepidermoid Esophageal Carcinoma:

Name: Mucoepidermoid Esophageal Carcinoma 12 14
Mucoepidermoid Carcinoma of the Esophagus 12
Esophageal Mucoepidermoid Carcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4686
NCIt 47 C5343
UMLS 69 C1333461

Summaries for Mucoepidermoid Esophageal Carcinoma

MalaCards based summary : Mucoepidermoid Esophageal Carcinoma, also known as mucoepidermoid carcinoma of the esophagus, is related to mucoepidermoid carcinoma and mixed oligodendroglioma-astrocytoma. An important gene associated with Mucoepidermoid Esophageal Carcinoma is WWOX (WW Domain Containing Oxidoreductase), and among its related pathways/superpathways is DNA Damage. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and kidney, and related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Mucoepidermoid Esophageal Carcinoma

Diseases related to Mucoepidermoid Esophageal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 10.2
2 mixed oligodendroglioma-astrocytoma 9.9 CEACAM5 TP53
3 lipid-cell variant infiltrating bladder urothelial carcinoma 9.9 CEACAM5 TP53
4 congenital granular cell tumor 9.9 CEACAM5 TP53
5 uterine corpus adenofibroma 9.9 CEACAM5 TP53
6 extramedullary plasmacytoma 9.9 CEACAM5 TP53
7 transient neonatal thrombocytopenia 9.9 CEACAM5 TP53
8 lacrimal gland mucoepidermoid carcinoma 9.9 CEACAM5 TP53
9 peritoneal serous adenocarcinoma 9.9 CEACAM5 TP53
10 gastrointestinal neuroendocrine tumor 9.9 CEACAM5 TP53
11 striated muscle rhabdoid tumor 9.9 CEACAM5 TP53
12 mucositis 9.9
13 adenocarcinoma 9.9
14 maxillary neoplasm 9.9 CEACAM5 TP53
15 dental caries 9.8 CEACAM5 TP53
16 nasal cavity disease 9.8 CEACAM5 TP53
17 vestibular gland benign neoplasm 9.8 CEACAM5 TP53
18 primary optic atrophy 9.8 TP53 WWOX
19 heavy chain disease 9.8 CEACAM5 TP53
20 villous adenocarcinoma 9.8 TP53 WWOX
21 serous cystadenocarcinoma 9.8 CEACAM5 TP53
22 red color blindness 9.8 TP53 WWOX
23 pancreatic somatostatinoma 9.8 CEACAM5 TP53
24 spinal cord dermoid cyst 9.8 TP53 WWOX
25 malignant acth producing neoplasm of pituitary gland 9.8 TP53 WWOX
26 male reproductive organ benign neoplasm 9.8 CEACAM5 TP53
27 molluscum contagiosum 9.8 TP53 WWOX
28 frontal sinus schneiderian papilloma 9.8 TP53 WWOX
29 arteritic anterior ischemic optic neuropathy 9.8 CEACAM5 TP53
30 trachea squamous cell carcinoma 9.8 CEACAM5 TP53
31 rectum sarcoma 9.7 CEACAM5 TP53
32 nominal aphasia 9.7 CEACAM5 TP53
33 benign shuddering attacks 9.7 CEACAM5 TP53
34 nail disorder, nonsyndromic congenital, 1 9.7 CEACAM5 TP53
35 acute porphyria 9.7 CEACAM5 TP53
36 leprosy 6 9.6 CEACAM5 TP53
37 gastric cancer, somatic 9.6 CEACAM5 TP53
38 hartnup disorder 9.5 CEACAM5 TP53
39 gastric fundus cancer 9.5 CEACAM5 TP53
40 teratoma 9.4 CEACAM5 TP53
41 deep angioma 9.3 CEACAM5 TP53 WWOX
42 gallbladder cancer 9.3 CEACAM5 TP53 WWOX
43 brown-vialetto-van laere syndrome 9.3 CEACAM5 TP53 WWOX
44 nail disorder, nonsyndromic congenital, 3, 9.3 CEACAM5 TP53 WWOX
45 ocular melanoma 9.1 TP53 WWOX

Graphical network of the top 20 diseases related to Mucoepidermoid Esophageal Carcinoma:



Diseases related to Mucoepidermoid Esophageal Carcinoma

Symptoms & Phenotypes for Mucoepidermoid Esophageal Carcinoma

GenomeRNAi Phenotypes related to Mucoepidermoid Esophageal Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.53 WWOX
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.53 WWOX
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.53 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.53 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.53 WWOX
6 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.53 WWOX
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.53 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.53 WWOX
9 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.53 WWOX TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.53 TP53 WWOX
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.53 TP53
12 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.53 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.53 TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.53 WWOX
15 Decreased viability with paclitaxel GR00293-A 8.96 TP53 WWOX

Drugs & Therapeutics for Mucoepidermoid Esophageal Carcinoma

Drugs for Mucoepidermoid Esophageal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
3 Liver Extracts Phase 3,Phase 2,Phase 1
4 Adjuvants, Anesthesia Phase 3
5 Analgesics Phase 3
6 Analgesics, Opioid Phase 3
7 Anesthetics Phase 3
8 Anesthetics, General Phase 3
9 Anesthetics, Intravenous Phase 3
10 Central Nervous System Depressants Phase 3
11 Narcotics Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Cola Nutraceutical Phase 3,Phase 2,Phase 1
14
Indinavir Approved Phase 2 150378-17-9 5362440
15
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
16
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
17
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
18
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
19
Docetaxel Approved May 1996, Investigational Phase 1, Phase 2 114977-28-5 148124 9877265
20 Anti-HIV Agents Phase 2
21 Anti-Infective Agents Phase 2,Phase 1
22 Anti-Retroviral Agents Phase 2
23 Antiviral Agents Phase 2,Phase 1
24 Cytochrome P-450 CYP3A Inhibitors Phase 2
25 Cytochrome P-450 Enzyme Inhibitors Phase 2
26 HIV Protease Inhibitors Phase 2
27
protease inhibitors Phase 2
28 Anti-Bacterial Agents Phase 1, Phase 2
29 Antibiotics, Antitubercular Phase 1, Phase 2
30 Antimetabolites Phase 1, Phase 2
31 Antimetabolites, Antineoplastic Phase 1, Phase 2
32 Topoisomerase Inhibitors Phase 1, Phase 2
33 Androgens Phase 1, Phase 2
34
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
35
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
36
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
37
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
38
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 446556 60843
39
Gemcitabine Approved Phase 1 95058-81-4 60750
40
Lenograstim Approved Phase 1 135968-09-1
41
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
43
leucovorin Approved, Nutraceutical Phase 1 58-05-9 143 6006
44
7-hydroxystaurosporine Experimental Phase 1 112953-11-4 72271
45
Camptothecin Experimental Phase 1 7689-03-4
46 Staurosporine Experimental Phase 1 62996-74-1
47
tipifarnib Investigational Phase 1 192185-72-1 159324
48 Adjuvants, Immunologic Phase 1
49 Albumin-Bound Paclitaxel Phase 1
50 Angiogenesis Inhibitors Phase 1

Interventional clinical trials:

(show all 15)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
3 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
4 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
5 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
6 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
7 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
8 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
9 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
10 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
11 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
12 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
13 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
14 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
15 Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy Terminated NCT01164566

Search NIH Clinical Center for Mucoepidermoid Esophageal Carcinoma

Genetic Tests for Mucoepidermoid Esophageal Carcinoma

Anatomical Context for Mucoepidermoid Esophageal Carcinoma

MalaCards organs/tissues related to Mucoepidermoid Esophageal Carcinoma:

39
Breast, Liver, Kidney, Lung, Brain

Publications for Mucoepidermoid Esophageal Carcinoma

Variations for Mucoepidermoid Esophageal Carcinoma

Expression for Mucoepidermoid Esophageal Carcinoma

Search GEO for disease gene expression data for Mucoepidermoid Esophageal Carcinoma.

Pathways for Mucoepidermoid Esophageal Carcinoma

Pathways related to Mucoepidermoid Esophageal Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.09 TP53 WWOX

GO Terms for Mucoepidermoid Esophageal Carcinoma

Biological processes related to Mucoepidermoid Esophageal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 8.62 TP53 WWOX

Sources for Mucoepidermoid Esophageal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....